<button id="eiezk"><video id="eiezk"></video></button>

產(chǎn)品名稱

PF 4693627 - PF 04693627

產(chǎn)品貨號(hào)

Axon 2020 CAS [1312815-93-2] MF C26H29Cl2N3O3MW 502.43 Purity: 100% Optical purity: d.e. >98% Soluble in DMSO Description Potent, selective and orally bioavailable inhibitor of microsomal prostaglandin E2 synthase-1 (mPGES-1) for the potential treatment of inflammation (IC50 value 3 nM and 109 nM in enzyme assay and WHB assay respectively). PF 4693627 shows excellent in vitro and in vivo properties and is selective against relevant human enzymes COX-2, TXAS, PGDS, 5-LOX, 15-LOX and 12-LOX. References Certificates Categories Extra info G.B. Arhancet et al. Discovery and SAR of PF-4693627, a potent, selective and orally bioavailable mPGES-1 inhibitor for the potential treatment of inflammation. Bioorg. Med. Chem. Lett. 2013, 23, 1114-1119. ? D.P. Walker et al. Synthesis and biological evaluation of substituted benzoxazoles as inhibitors of mPGES-1: use of a conformation-based hypothesis to facilitate compound design. Bioorg. Med. Chem. Lett. 2013, 23, 1120-1126. Certificate of Analysis Material Safety Data Sheet Cell Signaling & Oncology Immunology Pain & Inflammation mPGES-1 EC 5.3.99.3 Pfizer Licensed Products Selective and orally bioavailable inhibitor of mPGES-1 Chemical name 1-(5-chloro-6-(4-chlorophenyl)benzo[d]oxazol-2-yl)-N-((1S,3S)-3-(hydroxymethyl)cyclohexyl)piperidine-4-carboxamide Source information Pfizer compound; Sold for research purposes under agreement from Pfizer Inc. Parent CAS No. [1312815-93-2] Order Size Unit Price Stock 5 mg €125.00 In Stock

產(chǎn)品價(jià)格

現(xiàn)貨詢價(jià)，電話：010-67529703

產(chǎn)品規(guī)格

產(chǎn)品品牌

axonmedchem

產(chǎn)品概述

產(chǎn)品詳情

PF 4693627 - PF 04693627

Based on 14 reference(s) in Google Scholar 8 10 14

Axon 2020

CAS [1312815-93-2]

MF C26H29Cl2N3O3
MW 502.43

Purity: 100%
Optical purity: d.e. >98%
Soluble in DMSO

PF 4693627

Description

Potent, selective and orally bioavailable inhibitor of microsomal prostaglandin E2 synthase-1 (mPGES-1) for the potential treatment of inflammation (IC50 value 3 nM and 109 nM in enzyme assay and WHB assay respectively). PF 4693627 shows excellent in vitro and in vivo properties and is selective against relevant human enzymes COX-2, TXAS, PGDS, 5-LOX, 15-LOX and 12-LOX.

G.B. Arhancet et al. Discovery and SAR of PF-4693627, a potent, selective and orally bioavailable mPGES-1 inhibitor for the potential treatment of inflammation. Bioorg. Med. Chem. Lett. 2013, 23, 1114-1119.

D.P. Walker et al. Synthesis and biological evaluation of substituted benzoxazoles as inhibitors of mPGES-1: use of a conformation-based hypothesis to facilitate compound design. Bioorg. Med. Chem. Lett. 2013, 23, 1120-1126.

Certificate of Analysis
Material Safety Data Sheet

Cell Signaling & Oncology Immunology Pain & Inflammation mPGES-1 EC 5.3.99.3 Pfizer Licensed Products

Selective and orally bioavailable inhibitor of mPGES-1

Chemical name

1-(5-chloro-6-(4-chlorophenyl)benzo[d]oxazol-2-yl)-N-((1S,3S)-3-(hydroxymethyl)cyclohexyl)piperidine-4-carboxamide

Source information

Pfizer compound; Sold for research purposes under agreement from Pfizer Inc.

Parent CAS No.

[1312815-93-2]

產(chǎn)品資料

<button id="eiezk"><video id="eiezk"></video></button>